A decrease in the mitochondrial (mt) DNA to nuclear DNA ratio has gained acceptance as a marker of mitochondrial toxicity in treated HIV-infected patients, but the functional meaning of this alteration is unclear.
Methods
We assessed mtDNA content, mitochondrial content and function in peripheral blood mononuclear cells (PBMCs) of consecutive asymptomatic HIV-infected patients. Patients selected had been receiving a first-line highly active antiretroviral therapy (HAART) regimen for at least 6 months, consisting of zidovudine plus lamivudine or stavudine plus didanosine plus either nelfinavir or nevirapine, or were antiretroviral-naive. The mtDNA content was assessed by quantitative real-time PCR, mitochondrial content by citrate synthase activity, enzyme activity of complexes III and IV (both partially encoded by mtDNA) of the electron transport chain by spectrophotometry, oxygen consumption by polarography, and oxidative damage in cell membranes by monitoring cis-parinaric acid fluorescence.
Results
Mitochondrial content was significantly lower in all treated groups. Patients receiving stavudine plus didanosine had mtDNA depletion and a decrease in complex IV activity. However, oxygen consumption capacity and lipid peroxidation were unaffected in all groups.
Conclusion
Long-term HAART may induce mitochondrial abnormalities in PBMC mitochondria, which do not necessarily translate into functional abnormalities, at least in asymptomatic patients.
This study was presented in the 4th International Workshop on Adverse Drug Reactions & Lipodystrophy in HIV (San Diego, Calif., USA, September 2002) and in ‘Late Breakers & Hot Topics’ session in the 6th International Congress on Drug Therapy in HIV Infection (Glasgow, UK, November 2002).
References
1.
MartinJ.L., BrownC.E., Mattews-DavisN., & ReardonJ.E.Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis.Antimicrobial Agents & Chemotherapy1994; 38: 2743–2749.
2.
LimS.E., & CopelandW.C.Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase-γ.Journal of Biological Chemistry2001; 276(23): 616–623.
3.
LewisW., & DalakasM.C.Mitochondrial toxicity of antiviral drugs.Nature Medicine1995; 1: 417–422.
4.
BrinkmanK., ter HofstedeH.J., BurgerD.M., SmeitinkJ.A., & KoopmansP.P.Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.AIDS1998; 12: 1735–1744.
5.
CôtéH.C., BrummeZ.L., CraibK.J., AlexanderC.S., WynhovenB., TingL., WongH., HarrisM., HarriganP.R., O'ShaughnessyM.V., & MontanerJ.S.Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.New England Journal of Medicine2002; 346: 811–820.
6.
MoyleG.J., DattaD., MandaliaS., MorleseJ., AsboeD., & GazzardB.G.Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.AIDS2002; 16: 1341–1349.
MallolasJ., BlancoJ.L., PeñaJ.M.. Comparison of two HAART sequences in naive HIV-infected patients: a randomized, multicenter, open label, long term follow up clinical trial.XIV International AIDS Conference 2002. Barcelona, Spain, July 7–12 2002. Abstract TuOrB1186.
11.
BradfordM.A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding.Analytical Biochemistry1976; 72: 248–254.
12.
Rodriguez-SantiagoB., CasademontJ., & NunesV.Is mitochondrial DNA depletion involved in Alzheimer's disease?European Journal of Human Genetics2001; 9: 279–285.
13.
MorrisonT.B., WeisJ.J., & WittwerC.T.Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification.Biotechniques1998; 24: 954–958, 960, 962.
14.
RirieK.M., RasmussenR.P., & WittwerC.T.Product differentiation by analysis of DNA melting curves during the polymerase chain reaction.Analytical Biochemistry1997; 245: 154–160.
15.
BarrientosA.In vivo and in organello assessment of OXPHOS activities.Methods2002; 26(4): 307–316.
16.
RustinP., ChretienD., BourgeronT., GerardB., RotigA., SaudubrayJ.M., & MunnichA.Biochemical and molecular investigations in respiratory chain deficiencies.Clinica Chimica Acta1994; 228: 35–51.
17.
MiróO., BarrientosA., AlonsoJ.R., CasademontJ., JarretaD., Urbano-MarquezA., & CardellachF.Effects of general anesthetic procedures on mitochondrial function of human skeletal muscle.European Journal of Clinical Pharmacology1999; 55: 35–41.
18.
MiróO., CardellachF., BarrientosA., CasademontJ., RötigA., & RustinP.Cytochrome c oxidase assay in minute amounts of human skeletal muscle using single wavelength spectrophotometers.Journal of Neurosciences Methods1998; 80: 107–111.
19.
MiróO., AlonsoJ.R., JarretaD., CasademontJ., Urbano-MárquezA., & CardellachF.Smoking disturbs mitochondrial respiratory chain function and enhances lipid peroxidation in human circulating lymphocytes.Carcinogenesis1999; 20: 1331–1336.
20.
HedleyD., & ChowS.Flow cytometric measurement of lipid peroxidation in vital cells using parinaric acid.Cytometry1992; 13: 686–692.
21.
ShikumaC.M., HuN., MilneC., YostF., WaslienC., ShimizuS., & ShiramizuB.Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.AIDS2001; 15: 1801–1809.
22.
WalkerU.A., BickelM., Lutke VolksbeckS.I., KetelsenU.P., SchoferH., SetzerB., VenhoffN., RickertsV., & StaszewskiS.Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.Journal of Acquired Immune Deficiency Syndromes2002; 29: 117–121.
MiróO., GomezM., PedrolE., CardellachF., NunesV., & CasademontJ.Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy.AIDS2000; 14: 1855–1857.
25.
McComseyG., TanD.J., LedermanM., WilsonE., & WongL.J.Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy.AIDS2002; 16: 513–518.
VittecoqD., JardelC., BarthelemyC., EscautL., CheminotN., ChapinS., SternbergD., MaisonobeT., & LombesA.Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder?Journal of Acquired Immune Deficiency Syndromes2002; 31: 299–308.
28.
CossarizzaA., PintiM., MorettiL., BricalliD., BianchiR., TroianoL., FernandezM.G., BalliF., BrambillaP., MussiniC., & ViganoA.Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy.Journal of Infectious Diseases2002; 185: 299–305.
29.
WhiteD.J., MitalD., TaylorS., & St JohnJ.C.Sperm mitochondrial deletions as a consequence of long term highly active antiretroviral therapy.AIDS2001; 15(8): 1061–1062.
30.
RogeB.T., CalbetJ.A., MollerK., UllumH., HendelH.W., GerstoftJ., & PedersenB.K.Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels.AIDS2002; 16: 973–982.
31.
MartinA.M., HammondE., NolanD., PaceC., Den BoerM., TaylorL., MooreH., MartínezO.P., ChristiansenF.T., & MallalS.Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.American Journal of Human Genetics2003; 72(3): 549–560.
32.
GerardY., MaulinL., YazdanpanahY., De La TribonniereX., AmielC., MaurageC.A., RobinS., SablonniereB., DhennainC., & MoutonY.Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.AIDS2000; 14: 2723–2730.
33.
CarrA., MoreyA., MallonP., WilliamsD., & ThorburnD.R.Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.Lancet2001; 357: 1412–1414.
34.
ChurchJ.A., MitchellW.G., Gonzalez-GomezI., ChristensenJ., VuT.H., DimauroS., & BolesR.G.Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy.Journal of Pediatrics2001; 138: 748–751.
35.
BrivetF.G., NionI., MegarbaneB., SlamaA., BrivetM., RustinP., & MunnichA.Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction?Journal of Hepatology2000; 32: 364–365.
36.
PozniakA.L., StaszewskiS., GallantJ.. Comparison of the efficacy and safety of tenofovir disoproxil fumarate versus stavudine when used in combination with lamivudine and efavirenz in HIV-1 infected patients naive to antiretroviral therapy after 48 weeks of treatment: Study 903.6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 17–21 2002.
37.
BirkusG., HitchcockM.J.M., & CihlarT.Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.Antimicrobial Agents & Chemotherapy2002; 46(3): 716–723.
38.
CôtéH., NegredoE., RuizL.. Antiretroviral regimen-dependent mitochondrial DNA depletion in clinical samples from the SWATCH trial.9th Conference on Retroviruses & Opportunistic Infections. Seattle, Wash., USA, February 2002. Abstract 707.
39.
KelleyD.E., HeJ., MenshikovaE.V., & RitovV.B.Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes.Diabetes2002; 51(10): 2944–2950.
40.
WenchichL., ZemanJ., HansikovaH., PlavkaR., SperlW., & HoustekJ.Mitochondrial energy metabolism in very premature neonates.Biology of the Neonate2002; 81(4): 229–235.
41.
CapkovaM., HoustekJ., HansikovaH., HainerV., KunesovaM., & ZemanJ.Activities of cytochrome c oxidase and citrate synthase in lymphocytes of obese and normal-weight subjects.International Journal of Obesity & Related Metabolic Disorders2002; 26(8): 1110–1117.
42.
Muller-HockerJ., MuntauA., SchaferS., JakschM., StaudtF., PongratzD., & TaanmanJ.W.Depletion of mitochondrial DNA in the liver of an infant with neonatal giant cell hepatitis.Human Pathology2002; 33(2): 247–253.
43.
LedruE., ChristeffN., PateyO., de TruchisP., MelchiorJ.C., & GougeonM.L.Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution of the development of human immunodeficiency virus-associated lipodystrophy syndrome.Blood2000; 95: 3191–3198.
44.
MasanesF., BarrientosA., CebrianM., PedrolE., MiróO., CasademontJ., & GrauJ.M.Clinical, histological and molecular reversibility of zidovudine myopathy.Journal of the Neurological Sciences1998; 159(2): 226–228.
45.
MiróO., LópezS., MartínezE., Rodríguez-SantiagoB., BlancoJ.L., MilinkovicA.. Reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy.AIDS Research & Human Retroviruses2003; 19: 1027–1032.
